A Circulating Inhibitor (Anti-AcG) Specific for the Labile Factor-V of the Blood-Clotting Mechanism

Abstract

Study of the present hemorrhagic disorder establishes, without doubt, the presence of a powerful specific anti-AcG. The deprivation of AcG due to this inhibitor confirms the view that the labile factor plays a key role in the blood clotting system in at least two phases, namely, (1) during thromboplastin generation, and (2) later, during the conversion of prothrombin to thrombin. AcG is an essential component of many special clotting-test systems.